Eric Verdin, M.D., President and CEO
Eric Verdin, M.D., is the fifth President and Chief Executive Officer of The Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (M.D.) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a Professor of Medicine at UCSF.
Dr. Verdin joins the Buck from the Gladstone Institute for Virology and Immunology, where he served as Associate Director and Senior Investigator, focusing on the role of metabolism and diet in aging and on the chronic diseases of aging, including Alzheimer’s. His laboratory has focused on key proteins that play a central role in linking caloric restriction to increased healthspan and lifespan.
Dr. Verdin has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top one percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several prestigious scientific organizations including the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He serves on the Advisory Council of NIDA at the National Institutes of Health.
Dr. Verdin has extensive experience working with biotech companies. He is a founder of Acylin (purchased by Abbvie). He served on the scientific advisory boards of Elixir, Sirtris (purchased by GSK), of Calico (Google) and of Nokia, and also served as advisor to Sofinnova Ventures. Dr. Verdin has also worked for several years as consultant to Novartis, GSK, J&J, Altana, Roche and Pfizer and other biotech companies. Dr. Verdin is a resident of Marin County.